Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions.
Mjaess G, Haddad L, Jabbour T, Baudewyns A, Bourgeno HA, Lefebvre Y, Ferriero M, Simone G, Fourcade A, Fournier G, Oderda M, Gontero P, Bernal-Gomez A, Mastrorosa A, Roche JB, Abou Zahr R, Ploussard G, Fiard G, Halinski A, Rysankova K, Dariane C, Delavar G, Anract J, Barry Delongchamps N, Bui AP, Taha F, Windisch O, Benamran D, Assenmacher G, Benijts J, Guenzel K, Roumeguère T, Peltier A, Diamand R.
Mjaess G, et al. Among authors: assenmacher g.
Prostate Cancer Prostatic Dis. 2024 Jul 24. doi: 10.1038/s41391-024-00872-6. Online ahead of print.
Prostate Cancer Prostatic Dis. 2024.
PMID: 39048664